Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 18559419
Bierhoff H, Dundr M, Michels AA, Grummt I (2008) Phosphorylation by casein kinase 2 facilitates rRNA gene transcription by promoting dissociation of TIF-IA from elongating RNA polymerase I. Mol Cell Biol 28, 4988-98 18559419
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S170-p - TIF1A (human)
Modsite: KEGDVDVsDsDDEDD SwissProt Entrez-Gene
Orthologous residues
TIF1A (human): S170‑p, TIF1A (mouse): S168‑p
Characterization
Methods used to characterize site in vivo 2D analysis, [32P] bio-synthetic labeling, immunoprecipitation, mutation of modification site, phospho-antibody, phosphopeptide mapping, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  3T3 (fibroblast), HEK293T (epithelial), MEF (fibroblast), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
PHOSPHATASE CTDP1 (human)
KINASE CK2A1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE CTDP1 (human) transfection of wild-type enzyme, phospho-antibody, siRNA inhibition of enzyme, co-immunoprecipitation
KINASE CK2A1 (human) mutation in upstream enzyme recognition motif, phospho-antibody, pharmacological inhibitor of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DMAT decrease
Downstream Regulation
Effect of modification (function):  activity, induced, molecular association, regulation
Effect of modification (process):  cell cycle regulation, chromatin organization, altered, transcription, induced
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
TWISTNB (human) Disrupts co-immunoprecipitation

S172-p - TIF1A (human)
Modsite: GDVDVsDsDDEDDNL SwissProt Entrez-Gene
Orthologous residues
TIF1A (human): S172‑p, TIF1A (mouse): S170‑p
Characterization
Methods used to characterize site in vivo 2D analysis, [32P] bio-synthetic labeling, immunoprecipitation, mutation of modification site, phospho-antibody, phosphopeptide mapping, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  3T3 (fibroblast), HEK293T (epithelial), MEF (fibroblast), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
PHOSPHATASE CTDP1 (human)
KINASE CK2A1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE CTDP1 (human) transfection of wild-type enzyme, phospho-antibody, siRNA inhibition of enzyme, co-immunoprecipitation
KINASE CK2A1 (human) mutation in upstream enzyme recognition motif, phospho-antibody, pharmacological inhibitor of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DMAT decrease
Downstream Regulation
Effect of modification (function):  activity, induced, molecular association, regulation
Effect of modification (process):  cell cycle regulation, chromatin organization, altered, transcription, induced
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
TWISTNB (human) Disrupts co-immunoprecipitation